

Impact of type 2 Diabetes mellitus on pulmonary function tests

Rua,a Tariq Abdulsaid 1, Azza Sajid Jabbar 2 ,Talib Kadhim Akar 3

1. Clinical Pharmacist at Al-Fayhaa Teaching Hospital, Basrah Health Directory, Basrah city, Iraq, Email: ph.ruaa.tariq@gmail.com

2. Professor of Physiology at Department of pharmacology and toxicology, College of pharmacy, Basrah University. Basrah city, Iraq, Email: azza.jabbar@uobasrah.edu.iq

3. Assistant professor of internal medicine, college of medicine, university of Basrah

E mail:talibkadum@gmail.com

Abstract

Background: Diabetes mellitus is a chronic metabolic disorder that may affect different organs including the lungs. Different studies have been published on the effects of diabetes mellitus on pulmonary function. A restrictive pattern of lung disorder was reported in some studies, whereas an obstructive pattern was suggested in others. The study aims to determine the impact of type 2 diabetes on pulmonary function tests (PFTs) and the type of respiratory disorder. **Material and Methods:** This observational study was conducted in Basrah City, Iraq. One hundred and eighty-two participants were enrolled and divided into 2 groups: 100 healthy (group1) and 82 patients with type2 diabetes mellitus (group 2).PFTs were estimated by a medical spirometer and measurements of several hematological tests were done for each individual. **Results:** We found a significant decline ($p < 0.05$) in each of FEV1, FVC, PEF, and MVV and a significant increase in ELA in group 2. The restrictive pulmonary disorder was a higher percentage (24.39%) than obstruction (10.9%) and combined (2.43%). **Conclusion:** Pulmonary function tests were significantly affected by type2 DM and the percentages of different respiratory disorders were higher among group 2 than in group 1, with an increase in restrictive pattern.

Keywords: pulmonary function tests, DM2, restrictive pattern

Introduction

Type 2 diabetes mellitus (DM 2) includes a set of metabolic disorders that affects 12% of the middle-aged population (1). DM 2 leads to different health consequences and affects both large and small vessels, resulting in life-threatening microvascular and macrovascular diseases. (2) As a result, it has become one of the most serious risks to public health in the world. The problem becomes much more complicated when considering that up to half of all patients are completely clueless that they have this condition, as blood sugar can be elevated above normal levels in DM2 without noticeable signs (3).

Even though the fact that the lungs are not on the usual list of organs that might be impaired by diabetes, their intense vascularity, abundant collagen and elastin fibers place the pulmonary tissues as a possible target for hyperglycemia in the long term (4). Additionally, lung dysfunction develops more frequently in patients with poor glycemic control and who experienced a long period of metabolic illness (5). The metabolic condition of insulin resistance and insulin insufficiency, which is defined by high blood glucose levels, has a role in the disruption of collagen and elastin cross-linking. Lung elasticity is diminished as a result of this process (6).

Hyperinsulinemia promotes the growth and increase in the number of main human airway smooth muscle cells as well as their hyperresponsiveness and contractility in response to insulin, this outcome has been reported to be a possible reason for the link between wheezing and type 1 diabetes (7). Few studies have been done to conclude if subcutaneous insulin treatment is an independent contributor to the decline in lung function designated for DM2.

The most common way to assess lung function is by performing pulmonary function tests (PFTs) that includes three measures : diffusing capacity, lung volumes and spirometry (8). The purpose of a pulmonary function tests (PFTs) is to identify and characterize disease progressions that results in the decline in lung function. Obstruction of pulmonary airflow, lung volumes restriction, or a combination of both patterns; restrictive and obstructive abnormalities are examples of lung function impairments. (9) Although PFTs were created to measure airway function and lung disorders, their use has expanded to include a variety of specializations, and they can now be used as a basis for clinical decision-making in a variety of diseases (10). It is a valuable test for determining lung tissue enrolment in diabetes mellitus disease. The most

relevant measurements in this study are the forced vital capacity (FVC), The forced expiratory volume in the first second (FEV1), The ratio of FEV1 to FVC (FEV1/FVC%) which is used as an indicator of obstruction or restriction , peak expiratory flow (PEF), estimated lung age (ELA) and the maximal voluntary ventilation (MVV)(11).

We have designed this observational study to reveal the influence of diabetes mellitus type II on respiratory function tests as a primary endpoint and to determine the pattern of respiratory impairments.

Materials and methods

Study design

This is a cross-sectional observational study performed in Basra City, Iraq, from November 2021 to March 2022. It was carried out under the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) statement's recommendations for reporting observational studies (12).

Participants

The study included one hundred and eighty-two participants of both genders between the ages of 33 and 62 years. Participants were categorized into two groups according to their state of health: 100 healthy individuals (52 males and 48 females), within the range (33-57) years of age. The source of these groups was patients' relatives and university employees. This group is the control group (group 1). The other group (group 2) is 82 diabetic patients of (DM2) (38 male and 44 female) with age range of 37-62 years. The patients were on insulin therapy. They were randomly selected and the included and excluded criteria were taken into consideration. The source of this group was patients who attended the internal medicine consulting clinic at one of the major hospitals Al-Fayhaa Teaching Hospital, Basrah City, south of Iraq.

To rule out any abnormalities or disorders, all subjects underwent a thorough clinical and physical examination to examine their cardiovascular, pulmonary, neuromuscular, and musculoskeletal systems.

The study procedure was permitted by the University of Basrah's Ethical Committee and Basrah Health Directory.

Included criteria: Patients with DM2 who have been shifted to subcutaneous insulin therapy for at least six months after failure of oral antidiabetic medication to control blood glucose levels were included.

Excluded criteria: Patients with DM2 who are taking oral anti-diabetic medication, newly diagnosed patients who have not started taking oral anti-diabetic medication, patients with cough, sputum, dyspnea, wheezing, and other symptoms; smokers and patients with COPD or restrictive pulmonary condition; patients with cardiovascular disease or major diseases are all excluded (13) .

A detailed form of a questionnaire was used to acquire the demographics and features of all patients, including age, gender, height, weight, BMI, co-morbidities, drug intake, and smoking status.

Data sources and measurement

Pulmonary function tests

Spirometry is an old test and most commonly used to assess pulmonary function. PFTs were carried out in agreement with the current recommendations (14). Measurement of PFTs of patients and controls were assessed by a medical spirometer (Medical International Research MIR Spirolab III Diagnostic Spirometer, Rome, Italy). The measurements for all participants were between 9 am and 1 pm.

Spirometry was performed three times in a standing position at 15-minute intervals, and the best value was used. The recorded Parameters were (FVC) in liters, (FEV1), FEV1/FVC%, (MVV), (PEF) and (ELA), and the absolute values of participants were relied on in this study.

Echocardiogram

All patients went through an echocardiography examination by a cardiologist using GE vivid 7 cardiac ultrasound machine to exclude any cardiac disease that may affect pulmonary function test.

Laboratory measurements: For all participants, almost 5 mL of venous blood sample was collected in a serum separating tube, a sodium citrate, and ethylenediaminetetraacetic acid (EDTA) bulb using aseptic precautions.

A complete blood picture was estimated by SYSMEX XT-2000i, C-reactive protein (CRP) by Tina-quant CRP IV kit / COBAS INTEGRA, and ESR by Westergren method (15).

Diabetes mellitus was diagnosed according to a clinical picture and random blood sugar(200 mg/dL) *or* Fasting blood glucose level (126 mg/dL) *or* glycated Hemoglobin A1c $\geq 6.5\%$ (16). HbA1c of all the patients was estimated by the diagnostic tina-quant hemoglobin A1c kits of COBAS INTEGRA/ COBAS C SYSTEMS according to the current guidelines (17).

Participant's information was gathered in a collection form and later moved to a Microsoft excel sheet to be analyzed statistically.

Statistical Analysis

SPSS version 26 (The Statistical Package for Social Sciences) was used for statistical analysis. Mean and median comparisons, and Skewness, Shapiro–Wilk, and Kolmogorov–Smirnov tests were utilized to determine whether numerical data of normal distribution. For regularly distributed data, an independent sample t-test was utilized, and for the non-normal distribution data, the Mann–Whitney U–test was done. Spearman's rank and Pearson's correlation coefficients were used to determine the strength of the link between the two variables. A P-value of less than 0.05 was defined as a Statistical significance.

Results

For the two study groups (group 1 and 2) there were no significant differences ($p>0.05$) in main features such as age range, gender ratio, BMI, and weight. Furthermore, the two groups showed normal echocardiography. However, the difference was significant in HbA1c between the healthy control group and the diabetic group (4.6790 ± 0.43195 vs 8.4033 ± 1.16724 , $p < 0.05$), as illustrated in table 1. Then again, the comparison between the two groups revealed several variations in hematological parameters as seen in table 2. Each WBC count and neutrophils count were highly increased ($p < 0.05$) in group 2 in comparison to group 1; respectively (8.0119 ± 2.01718 vs. 7.0725 ± 1.58030) and (4.8655 ± 1.39052 vs. 4.1851 ± 1.41110). While no significant change in lymphocytes count was found ($p > 0.05$). Regarding RBC and other indices, there were no significant differences found in each of RBC, MCHC, and HGB (p

>0.05). Inflammatory markers such as CRP and ESR were significantly increased ($p < 0.05$) in group 2 in comparison to group 1; respectively (10.37 ± 4.188 vs. 6.06 ± 2.199) and (1.7052 ± 1.18485 vs. 0.7890 ± 0.16808).

We found variations in the results of PFTs. Each of FVC (3.18 ± 0.54478 VS. 3.8509 ± 0.80620) and MVV (83.6971 ± 18.3042 VS. 108.1568 ± 16.14099) were significantly decreased in group 2 ($p > 0.05$). While ELA was significantly increased (70.9857 ± 14.28843 vs. 45.4754 ± 17.07687) in group 2, as illustrated in table 3. On the other hand, there were no significant differences that we discovered in each of FEV1, FEV1% and PEF between the two groups. Furthermore, the statistical analysis uncovered that there were variations in the percentage of respiratory disorders (obstructive, restrictive, and combined cases) between group 1 and group 2. The obstructive diseases percentage in group 1 was (5%) while it was (10.9%) in group 2. As well as the percentage of restrictive disease in group 2 (24.39%) was higher than that in group 1 (9%). There were no combined cases in group 1, while it was 2% in group 2. Normal respiratory case percentage in group 1 was higher (86%) than what we found in group 2 (62.19%), (Table 4). The same table shows that the ELA of the obstructive patients in group 2 was significantly elevated than that of obstructive patients of group 1 (69.10 ± 15.34 vs. 54.27 ± 15.46) $p < 0.05$. The same finding was reported related to the ELA comparison of the restrictive patients between the two groups (64.55 ± 10.29 vs. 52.22 ± 12.66). Moreover ELA was also significantly elevated in the normal respiratory cases of the group 2 (58.50 ± 9.19) compared to the normal respiratory cases of group 1 (43.49 ± 15.006), $p > 0.05$ as shown in table 4. However, the correlations between HbA1c and each of FEV1, FVC, FEV1%, PEF, and MVV were non-significant, ($p > 0.05$). The interesting finding was the significant positive correlation between ELA and HbA1c ($r: 0.33$, $p > 0.05$), as seen in table 5.

Table 1: Characteristics of the groups

Group	Group 1	Group 2	*P-value
Parameters	Mean ±SD	Mean ±SD	
Numbers	100	82	
Age range	33-57	37-62	
Gender ratio Female/male ratio)	48:52	44:38	0.261
Weight (kg)	71.9109±14.81492	81.8921±7.63179	0.951
height (cm)	168.7723±9.54032	170.1770±9.42042	0.343
BMI (Kg/cm ²)	25.1468±4.37321	28.5130±3.99381	0.251
HbA1c	4.6790±0.43195	8.4033±1.16724	0.000
Echocardiography	Normal	Normal	

* P-value is considered a significant at a level less than 0.05, mean±SD: mean ± standard deviation

Table 2: Hematological indices; ESR and CRP in group 1 and group 2

Group	Group1	Group 2	*P-value
parameters	Mean ±SD	Mean ±SD	
RBC	4.9249±0.61352	4.8593±0.42543	0.410
WBC	7.0725±1.58030	8.0119±2.01718	0.001
NEUTROPHILS	4.8655±1.39052	4.1851±1.41110	0.002
LYMPHOCYTES	2.5670±0.78250	2.5244±0.78498	0.727
HCT	42.8429±4.18492	40.0671±4.41200	0.000
HGB	13.4624±1.54295	13.3213±1.52669	0.765
MCV	88.6869±6.69983	82.3400±5.17271	0.000
MCH	30.8799±2.89249	28.8692±1.96729	0.000
MCHC	33.9390±1.39665	34.3557±2.04951	0.116
ESR	6.06± 2.199	10.37±4.188	0.000
CRP	0.7890±0.16808	1.7052±1.18485	0.000

* P-value is considered a significant at a level less than 0.05, RBC: red blood cells; WBC: white blood cells; HGB: hemoglobin; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; and MCHC: mean corpuscular hemoglobin concentration; ESR: erythrocytes sedimentation rate; CRP: C-reactive protein.

Table 3: Pulmonary function tests in group 1 and group 2

Group	Group 1	Group 2	*P-value
Parameters	Mean ±SD	Mean ±SD	
FEV1(L)	3.21±0.74335	2.7163±0.67216	0.061
FVC(L)	3.8509±0.80620	3.18±0.54478	0.000
FEV1%(L)	90.8610±5.96569	84.9500±9.91571	0.188
PEF(L/S)	6.5036±2.01696	4.5398±1.07341	0.0821
MVV(L/S)	108.1568±16.14099	83.6971±18.30421	0.000
ELA (years)	45.4754±17.07687	70.9857±14.28843	0.000

*P-value is considered a significant at a level less than 0.05.

Table 4: Respiratory diagnosis and ELA in group 1 and group 2

Respiratory diagnosis	Group 1 N (%)	Group 1 ELA Mean ± SD	Group 2 N (%)	Group 2 ELA Mean ± SD	*P-value
Obstructive	5(5)	54.27±15.46	9(10.9)	69.10±15.341	0.0021
Restrictive	9 (9)	52.22±12.66	20(24.39)	64.55±10.29	0.0016
Combined	0 (0)		2(2.43)	75.30±13.02	
Normal	86(86)	43.49±15.006	51(62.19)	58.50±9.19	0.000

N: number; ELA: estimated lung age; *P-value is significant at a level less than 0.05

Table 5: Correlation between PFT and HbA1c in group 2

HbA1c	FVC	FEV1	FEV1%	PEF	ELA	MVV
r value	-0.059	-0.033	-0.274	-0.023	0.33	-0.028
P value	0.625	0.787	0.0721	0.850	0.000	0.819

Discussion

Pulmonary function tests, including FVC, FEV₁, FEV₁ percent, PEF_R, and MVV of patients with DM 2 (group 2) showed a significantly lower values than in healthy controls (group 1). These findings are consistent with prior researches (5,18), which found that diabetes has a negative impact, especially when it is long-term and requires insulin administration. On the other hand, these results are inconsistent with previous study (19). More than half of the diabetic patients (62.19 %) had normal pulmonary function tests, but (35.2%) had asymptomatic evidence of disturbed lung function tests – most commonly was a restrictive pattern (24.39 %), followed by obstructive (10.9 %), and mixed (2.43 %). This outcome was also described by the Fremantle diabetes study (20), which stated that diabetes might be complicated by lower lung volumes and airflow limitation. Thus, the study findings came consistent with those of others, indicating that type 2 diabetes mellitus has an adverse impact on pulmonary functions and that the impairment is predominantly restrictive (4,21). This finding may be explained by the fact that connective tissues in the lungs undergo glycosylation due to persistent hyperglycemia which may reduce the elastic recoil of the lungs and develop local inflammation in lung tissues, that eventually leads to a restrictive ventilatory changes (13).

In this study, 9 patients were with the obstructive pulmonary pattern. Some recent studies suggested an obstructive pathology of the lungs (22). Theusen BH et al (23) showed in their study that insulin resistance is an important predictor of the occurrence of symptoms that resembles asthma symptoms. While Balducci et al revealed that in DM 2, the strength of respiratory muscle declines corresponding to the metabolic regulation of the disease which may lead to reduced lung volumes (24). Another study conducted by Fuso L et al showed a distinct relationship between respiratory muscle efficacy and glycemic regulation. It demonstrated that MVV which is a measure of the respiratory muscle performance, lung volume variations, and airway resistance is elevated in patients with good control of blood glycemic levels and reduced in others with poorly controlled glycemia. This finding is consistent with our study that showed a statistically significant decrease in MVV of DM patients compared to their non-diabetics controls (25). However, MVV can be utilized as a simple means for the assessment of respiratory muscle strength (26). Furthermore, another interesting finding we have found is the significant elevation in ELA of the diabetic patients (group 2). ELA is the person's real age when respiratory functions

are normal(27). Deterioration of PFTs was inversely linked with ELA, implying that ELA increased as PFTs deteriorated(28) We suggest that significantly affected pulmonary function in DM type 2 on insulin and expressing a restrictive pattern could be explained by several reasons: Though morbid obesity had been excluded (two patients) , yet there are sizable number of overweight(33 patient) and obese (27 patient),a factor that might contribute to the restrictive derangement of respiratory function test(29,30); Long standing DM may cause autonomic neuropathy that may associated with Gastroesophageal Reflux Disease (GERD) which may lead to recurrent aspiration pneumonitis and consequent fibrotic parenchymal lung changes and there is a high incidence of infections among DM patient (such as pulmonary tuberculosis) that may leave marked fibrotic changes in lung (31).

In this study, we could not find any relationship between HbA1c levels and PFTs results during the time of pulmonary function measurements which came consistent with Mori H et al study(32) and Benbassat CA et al(33) except for ELA that showed highly significant correlation with HbA1c.They attributed these results to the fact that HbA1c measurements indicate glycemic regulation for a short time (1-2 months). However, the absence of a significant relationship between spirometric parameters and glycemic control of patients indicates a more complicated model of lung damage caused by diabetes.

Regarding the hematological indices, group 2 showed a statistically significant increase in total WBC ($P < 0.05$) and absolute neutrophil counts ($P < 0.05$) in comparison to controls (group 1), which came close to another study by Biadgo B et al (34). When DM2 patients were compared to the healthy control group, statistically significant increases in MCV, MCH, and HCT ($P < 0.05$) were detected. According to Chen LK et. al., a higher WBC count was significantly related to insulin resistance in elderly middle-aged patients (35). However, there was no link found between insulin resistance and RBC count. Furthermore, we found that both ESR and CRP were significantly elevated in group 2. They are sensitive blood inflammatory markers might be used to evaluate certain inflammatory processes and infections in DM (36) .It has been reported by Mottaghi et al that their levels were significantly associated with the progress of DM (37).

Conclusion

Pathological process of Diabetes mellitus may extend to include lung physiology. Pulmonary function tests were significantly affected by DM2 and the percentages of different respiratory disorders were higher among group 2 than group 1, with an increase of restrictive pattern.

Acknowledgments

The authors would like to thank Dr. Labeed Abdullah Al-Saad, College of Pharmacy University of Basrah for his efforts in statistical analysis and Dr. Abdulameer Abdulbari Abdulhamid, Assistant professor at College of Medicine, University of Basrah for his role in the echocardiographic examination of patients.

References

1. Unwin N, Gan D, Whiting D. The IDF Diabetes Atlas: Providing evidence, raising awareness and promoting action. *Diabetes Res Clin Pract.* 2010;87(1):2–3.
2. Forbes JM, Cooper ME. Mechanisms of diabetic complications. *Physiol Rev.* 2013;93(1):137–88.
3. Soriguer F, Goday A, Bosch-Comas A, Bordiú E, Calle-Pascual A, Carmena R, et al. Prevalence of diabetes mellitus and impaired glucose regulation in Spain: The Di@bet.es Study. *Diabetologia.* 2012;55(1):88–93.
4. Sampol G, Lecube A. Type 2 diabetes and the lung: A bidirectional relationship. *Endocrinol y Nutr (English Ed [Internet].* 2012;59(2):95–7. Available from: <http://dx.doi.org/10.1016/j.endoen.2012.02.003>
5. Teeter JG, Riese RJ. Cross-sectional and prospective study of lung function in adults with type 2 diabetes: The atherosclerosis risk in communities (ARIC) study. *Diabetes Care.* 2008;31(10).
6. AMERICAN DIABETES ASSOCIATION. Diagnosis and classification of diabetes mellitus. *Diabetes Care.* 2008;31(SUPPL. 1).
7. Singh S, Bodas M, Bhatraju NK, Pattnaik B, Gheware A, Parameswaran PK, et al.

Hyperinsulinemia adversely affects lung structure and function. *Am J Physiol - Lung Cell Mol Physiol*. 2016;310(9):L837–45.

8. Sewa DW, Ong TH. Pulmonary function test: Spirometry. *Proc Singapore Healthc*. 2014;23(1):57–64.
9. Glady CA, Aaron SD, Lunau M, Clinch J, Dales RE. A spirometry-based algorithm to direct lung function testing in the pulmonary function laboratory. *Chest* [Internet]. 2003;123(6):1939–46. Available from: <http://dx.doi.org/10.1378/chest.123.6.1939>
10. Mohammed SH, Jabbr AS, Ibrahim NK. Impact of parasitic infection with *Ascaris lumbricoides* on pulmonary function tests in asthmatic and non-asthmatic children. *Respir Med Case Reports* [Internet]. 2021;34(July):101552. Available from: <https://doi.org/10.1016/j.rmcr.2021.101552>
11. Paramothayan S. *Essential respiratory medicine*. John Wiley & Sons; 2019.
12. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. *Int J Surg* [Internet]. 2014;12(12):1495–9. Available from: <http://dx.doi.org/10.1016/j.ijssu.2014.07.013>
13. Shah SH, Sonawane P, Nahar P, Vaidya S, Salvi S. Pulmonary function tests in type 2 diabetes mellitus and their association with glycemic control and duration of the disease. *Lung India*. 2013;30(2):108–12.
14. Graham BL, Steenbruggen I, Barjaktarevic IZ, Cooper BG, Hall GL, Hallstrand TS, et al. Standardization of spirometry 2019 update an official American Thoracic Society and European Respiratory Society technical statement. *Am J Respir Crit Care Med*. 2019;200(8):E70–88.
15. Litao MKS, Kamat D. Erythrocyte sedimentation rate and C-reactive protein: How best to use them in clinical practice. *Pediatr Ann*. 2014;43(10):417–20.
16. Harrison TR, Jameson JL. *Harrison's Principles of Internal Medicine* | Principles of Internal Medicine. McGraw-Hill Education; 2018.

17. Weykamp C. HbA1c: A review of analytical and clinical aspects. *Ann Lab Med.* 2013;33(6):393–400.
18. Nuiman MAK. Reduced Pulmonary Function in Type 2. *Diabetes Care.* 2004;i(August 2003).
19. Alkinany ASG. Pulmonary function tests in male patients with type II diabetes mellitus. *J Basrah Res.* 2013;39(3).
20. Davis TME, Knuiman M, Kendall P, Vu H, Davis WA. Reduced pulmonary function and its associations in type 2 diabetes: The Fremantle Diabetes Study. *Diabetes Res Clin Pract.* 2000;50(2):153–9.
21. Mittal S. Evaluation of Pulmonary Functions in Patients of Type 2 Diabetes Mellitus : a Cross-sectional Study. 2022;i:1–11.
22. Rogliani P, Ora J, Di Daniele N, Lauro D. Pleiotropic effects of hypoglycemic agents: implications in asthma and COPD. *Curr Opin Pharmacol* [Internet]. 2018;40:34–8. Available from: <http://dx.doi.org/10.1016/j.coph.2018.01.002>
23. Thuesen BH, Husemoen LLN, Hersoug LG, Pisinger C, Linneberg A. Insulin resistance as a predictor of incident asthma-like symptoms in adults. *Clin Exp Allergy.* 2009;39(5):700–7.
24. Balducci, Stefano, Sacchetti, Massimo, Haxhi, Jonida, Orlando, Giorgio, D’Errico, Valeria, Fallucca, Sara, Menini, Stefano, Pugliese G. Physical Exercise as therapy for type II diabetes. *Diabetes Metab Res Rev* [Internet]. 2014;32(30):13–23. Available from: <http://libweb.anglia.ac.uk/>
25. Fuso L, Pitocco D, Condoluci C, Conte E, Contu C, Rizzi A, et al. Decline of the lung function and quality of glycemic control in type 2 diabetes mellitus. *Eur J Intern Med* [Internet]. 2015;26(4):273–8. Available from: <http://dx.doi.org/10.1016/j.ejim.2015.02.022>
26. Gibson GJ, Whitelaw W, Siafakas N, Supinski GS, Fitting JW, Bellemare F, et al. ATS/ERS Statement on respiratory muscle testing. *Am J Respir Crit Care Med.* 2002;166(4):518–624.
27. Al-jadaan, S. A., & JabbarAlkinany AS. Impact of benzene exposure on lung functions of fuel stations workers in Basra City, Southren of Iraq. *Int J Pharm Sci Heal Care.*

2017;2(7):31–6.

28. Jabbar AS, Mohammed RN. Impact of paints exposure on pulmonary function tests of male workers in basrah city,south of Iraq. *Int J Pharm Res.* 2020;12(2):1322–8.
29. Noori IF, Jabbar AS. Impact of weight reduction surgery on static and dynamic lung volumes. *Ann Med Surg [Internet].* 2021;66(June):102457. Available from: <https://doi.org/10.1016/j.amsu.2021.102457>
30. Mason RJ, Broaddus VC, Martin TR, King TE, Schraufnagel D, Murray JF, et al. *Murray and Nadel's Textbook of Respiratory Medicine E-Book: 2-Volume Set.* Elsevier Health Sciences; 2010.
31. Walker BR, Colledge NR. *Davidson's principles and practice of medicine e-book.* Elsevier Health Sciences; 2013.
32. Mori H, Okubo M, Okamura M, Yamane K, Kado S, Egusa G, et al. abnormalities of pulmonary function in patients with non-insulin-dependent diabetes mellitus. 1992;31(2).
33. Benbassat CA, Stern E, Kramer M, Lebzelter J, Blum I, Fink G. Pulmonary function in patients with diabetes mellitus. *Am J Med Sci [Internet].* 2001;322(3):127–32. Available from: <http://dx.doi.org/10.1097/00000441-200109000-00003>
34. Biadgo B, Melku M, Abebe SM, Abebe M. Hematological indices and their correlation with fasting blood glucose level and anthropometric measurements in type 2 diabetes mellitus patients in Gondar, Northwest Ethiopia. *Diabetes, Metab Syndr Obes Targets Ther.* 2016;9:91–9.
35. Chen LK, Lin MH, Chen ZJ, Hwang SJ, Chiou ST. Association of insulin resistance and hematologic parameters: Study of a middle-aged and elderly Chinese population in Taiwan. *J Chinese Med Assoc [Internet].* 2006;69(6):248–53. Available from: [http://dx.doi.org/10.1016/S1726-4901\(09\)70251-5](http://dx.doi.org/10.1016/S1726-4901(09)70251-5)
36. Wang Y, Yang P, Yan Z, Liu Z, Ma Q, Zhang Z, et al. The Relationship between Erythrocytes and Diabetes Mellitus. *J Diabetes Res.* 2021;2021.
37. Tayebbeh Mottaghi FK, Khorvash F, Mohammadreza M, Kheirrollahi M, Askari G.

Association Between BMI and Inflammation Among Diabetic Polyneuropathy Patients

Abstract. Int J Prev Med. 2019;8.